At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
UNCY Unicycive Therapeutics, Inc.
Post-Market Trading 11-25 19:32:34 EST
0.5526
+0.0226
+4.26%
盘后0.5449
-0.0077-1.39%
19:31 EST
High0.5587Low0.5301Vol1.30M
Open0.5433D1 Closing0.5300Amplitude5.40%
Mkt Cap57.36MTradable Cap33.96MTotal Shares103.80M
T/O710.75KT/O Rate2.12%Tradable Shares61.45M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--
Unicycive Therapeutics Price Target Maintained With a $3.00/Share by Benchmark
Dow Jones  ·  11-22
Unicycive Therapeutics Price Target Maintained With a $3.00/Share by Benchmark
Unicycive Therapeutics to Participate in Two Upcoming Investor Conferences Including a Fireside Chat at the Piper Sandler 36th Annual Healthcare Conference
GlobeNewswire  ·  11-21
Unicycive Therapeutics to Participate in Two Upcoming Investor Conferences Including a Fireside Chat at the Piper Sandler 36th Annual Healthcare Conference
Strategic Market Position and FDA Milestone Propel Unicycive Therapeutics to ‘Buy’ Rating
TIPRANKS  ·  11-15
Strategic Market Position and FDA Milestone Propel Unicycive Therapeutics to ‘Buy’ Rating
BRIEF-Unicycive Announces Q3 2024 Financial Results And Provides Business Update
Reuters  ·  11-13
BRIEF-Unicycive Announces Q3 2024 Financial Results And Provides Business Update
Unicycive Therapeutics reports Q3 EPS (13c), consensus (15c)
TIPRANKS  ·  11-13
Unicycive Therapeutics reports Q3 EPS (13c), consensus (15c)
Unicycive Therapeutics Q3 Income From Operations USD -6.251 Million
THOMSON REUTERS  ·  11-13
Unicycive Therapeutics Q3 Income From Operations USD -6.251 Million
Unicycive Announces Third Quarter 2024 Financial Results and Provides Business Update
THOMSON REUTERS  ·  11-13
Unicycive Announces Third Quarter 2024 Financial Results and Provides Business Update
Unicycive Therapeutics Inc Q3 Shr View $-0.15 -- Lseg Ibes Data
THOMSON REUTERS  ·  11-13
Unicycive Therapeutics Inc Q3 Shr View $-0.15 -- Lseg Ibes Data
Press Release: Unicycive Announces Third Quarter 2024 Financial Results and Provides Business Update
Dow Jones  ·  11-13
Press Release: Unicycive Announces Third Quarter 2024 Financial Results and Provides Business Update
Unicycive Therapeutics Says FDA Accepts New Drug Application for Oxylanthanum Carbonate
MT Newswires Live  ·  11-11
Unicycive Therapeutics Says FDA Accepts New Drug Application for Oxylanthanum Carbonate
Unicycive: FDA to Review Lead Drug Candidate for Hyperphosphatemia
Dow Jones  ·  11-11
Unicycive: FDA to Review Lead Drug Candidate for Hyperphosphatemia
Unicycive Therapeutics announces U.S. FDA acceptane for NDA for OLC
TIPRANKS  ·  11-11
Unicycive Therapeutics announces U.S. FDA acceptane for NDA for OLC
Unicycive Therapeutics Announces U.S. FDA Acceptance of the New Drug Application (Nda) for Oxylanthanum Carbonate (Olc) for the Treatment of Hyperphosphatemia in Patients With Chronic Kidney Disease on Dialysis
THOMSON REUTERS  ·  11-11
Unicycive Therapeutics Announces U.S. FDA Acceptance of the New Drug Application (Nda) for Oxylanthanum Carbonate (Olc) for the Treatment of Hyperphosphatemia in Patients With Chronic Kidney Disease on Dialysis
Unicycive Therapeutics Inc - Preparing for 2025 Commercial Launch of Olc
THOMSON REUTERS  ·  11-11
Unicycive Therapeutics Inc - Preparing for 2025 Commercial Launch of Olc
Unicycive Therapeutics Inc - FDA Sets Pdufa Action Date of June 28, 2025
THOMSON REUTERS  ·  11-11
Unicycive Therapeutics Inc - FDA Sets Pdufa Action Date of June 28, 2025
Unicycive Therapeutics Announces U.S. FDA Acceptance of the New Drug Application (NDA) for Oxylanthanum Carbonate (OLC) for the Treatment of Hyperphosphatemia in Patients with Chronic Kidney Disease on Dialysis
GlobeNewswire  ·  11-11
Unicycive Therapeutics Announces U.S. FDA Acceptance of the New Drug Application (NDA) for Oxylanthanum Carbonate (OLC) for the Treatment of Hyperphosphatemia in Patients with Chronic Kidney Disease on Dialysis
Unicycive presents on development progress of oxylanthanum carbonate
TIPRANKS  ·  10-28
Unicycive presents on development progress of oxylanthanum carbonate
Unicycive Therapeutics Delivers Multiple Poster Presentations Highlighting Development Progress on Oxylanthanum Carbonate (OLC) and UNI-494 at the American Society of Nephrology (ASN) Kidney Week 2024
GlobeNewswire  ·  10-28
Unicycive Therapeutics Delivers Multiple Poster Presentations Highlighting Development Progress on Oxylanthanum Carbonate (OLC) and UNI-494 at the American Society of Nephrology (ASN) Kidney Week 2024
Unicycive Therapeutics, Inc. (NASDAQ:UNCY): Is Breakeven Near?
Simply Wall St.  ·  10-16
Unicycive Therapeutics, Inc. (NASDAQ:UNCY): Is Breakeven Near?
Unicycive Therapeutics Announces Late-Breaker Poster Presentation on Oxylanthanum Carbonate (OLC) at the American Society of Nephrology (ASN) Kidney Week 2024
GlobeNewswire  ·  10-14
Unicycive Therapeutics Announces Late-Breaker Poster Presentation on Oxylanthanum Carbonate (OLC) at the American Society of Nephrology (ASN) Kidney Week 2024

Introduction

Company Name.
Unicycive Therapeutics, Inc.
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Unicycive Therapeutics, Inc., a biotechnology company, develops treatments for various medical conditions in the United States. Its drug candidates include UNI 494, a pro-drug of Nicorandil that is being developed as a treatment for acute kidney injury; and Renazorb (Oxylanthanum Carbonate), which is being developed for the treatment of hyperphosphatemia in patients with chronic kidney disease. Unicycive Therapeutics, Inc. has license agreements with Shilpa Medicare Ltd; Sphaera Pharma Pte. Ltd.; Syneos Health LLC; Inotiv; Lee's Pharmaceutical (HK) Limited; Celerion; and Lotus International Pte Ltd. The company was incorporated in 2016 and is based in Los Altos, California.
Issue price:
--